Business Context and Reporting Period
This Form 8-K is a current report filed by OncoCyte Corporation (not Insight Molecular Diagnostics Inc.) on November 14, 2017. The filing serves to announce the company's financial results for the three and nine months ended September 30, 2017. The registrant is an emerging growth company incorporated in California.
Key Financial Metrics
The filing text itself does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are detailed in the press release attached as Exhibit 99.1, which is incorporated by reference but not reproduced in the body of this 8-K.
Material Changes
No specific material changes or comparative data versus prior periods are provided in the text of this filing. The document solely references the attached press release for the results of operations and financial condition.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The filing includes a standard disclaimer that statements containing words such as "may," "will," "believes," or "expects" are forward-looking and subject to risks.
- Risk Factors: Investors are directed to the "Risk Factors" section of OncoCyte Corporation's Form 10 for additional factors that could cause actual results to differ materially from anticipated results.
- Management Commentary: No specific management commentary or outlook is included in the 8-K text; it refers readers to the press release for details.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) in Exhibit 99.1 (Press Release dated November 14, 2017).
- Confirm the company name is OncoCyte Corporation, as the input metadata referenced "Insight Molecular Diagnostics Inc."
- Review the "Risk Factors" in the company's Form 10 for potential impacts on future performance.
- Note that the company has elected to use the extended transition period for complying with new financial accounting standards as an emerging growth company.